



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Application of:

Dirk M. Anderson and Laurent J. Galibert

Docket No.: 2874-B

Group Art Unit: 1646

Serial No: 09/705,985

Examiner: N. Basi

Filed: November 3, 2000

For: METHOD OF INHIBITING OSTEOCLAST ACTIVITY

RECEIVED

NOV 23 2004  
NOV 23 2004

**SECOND SUPPLEMENTAL  
INFORMATION DISCLOSURE STATEMENT**

TECH CENTER 2800  
TECH CENTER 1600/2900

Mail Stop Amendment  
Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Pursuant to the duty of disclosure as set forth in 37 C.F.R. §1.56, §1.97 and §1.98, applicants hereby disclose publications known to them which may be material to the patentability of this invention. The publications are listed on the attached Form PTO-1449, and copies are enclosed. Kindly acknowledge receipt of this Supplemental Statement and make the cited references of record in the subject application.

This Supplemental Information Disclosure Statement is being filed after the mailing date of the first Office action on the merits, but before the mailing date of either a final action under § 1.113 or a notice of allowance under § 1.311. The above-cited references are submitted under §1.97(c) and accompanied by the fee of \$180 as set forth in §1.17(p).

Please charge Deposit Account No. 09-0089 in the amount of \$180. An original and one copy of this sheet are enclosed. The Commissioner is hereby authorized to charge any additional fees which may be required or credit any overpayment to Deposit Account No. 09-0089.

Applicants request consideration of this information and passage of the application to issue.

11/22/2004 AWONDAF1 00000014 090089 09705985  
01 FC:1806 180.00 DA

Respectfully submitted,

Diana K. Sheiness  
Attorney/Agent for Applicants  
Registration No.: 35,356  
Phone: (206) 265-7818

Please send all future correspondence to:  
22932  
Immunex Corporation  
Law Department  
1201 Amgen Court West  
Seattle, Washington 98119-3105  
(206) 265-7000

**CERTIFICATE OF MAILING**

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to the Mail Stop Amendment, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on the date appearing below.

November 15, 2004

Date

Signature

**Form PTO-1449**U.S. DEPARTMENT OF COMMERCE  
PATENT AND TRADEMARK OFFICE

ATTY. DOCKET NO. -

2874-B

SERIAL NO.

09/705,985

**2<sup>nd</sup> Supplemental  
INFORMATION DISCLOSURE CITATION**

APPLICANT

Dirk M. Anderson et al.

FILING DATE

November 3, 2000

GROUP

1646

(Use several sheets if necessary)

**U.S. PATENT DOCUMENTS**

EXAMINER		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
		6,271,349	08/07/01	Dougall et al.			
		6,419,929	07/16/02	Anderson			
		6,528,482	03/04/03	Anderson et al.			
		6,537,763	03/25/03	Dougall et al.			
		6,740,522	05/25/04	Anderson			

**RECEIVED**NOV 23 2004  
NOV 20 2004TECH CENTER 2000  
TECH CENTER 1000**FOREIGN PATENT DOCUMENTS**

		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION YES	NO
		WO 94/10308	11/05/94	PCT				
		WO 96/40918	19/12/96	PCT				
		WO 99/29865	17/06/99	PCT				

**OTHER DOCUMENTS** (Including Author, Title, Date, Pertinent Pages, Etc.)

		Takahashi N et al., "A new member of tumor necrosis factor ligand family, ODF/OPGL/TRANCE/RANKL, regulates osteoclast differentiation and function," <i>Biochem Biophys Res Commun</i> 1999; 256:449-455.
		Tsukii K et al., "Osteoclast differentiation factor mediates an essential signal for bone resorption induced by 1 $\alpha$ ,25-dihydroxyvitamin D <sub>3</sub> , prostaglandin E <sub>2</sub> , or parathyroid hormone in the microenvironment of bone," <i>Biochem Biophys Res Commun</i> 1998; 246:337-341.
		Wiley, SR et al., "Identification and characterization of a new member of the TNF family that induces apoptosis," <i>Immunity</i> 1995; 3(6):673-682.

EXAMINER

DATE CONSIDERED

\*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.